ArticleScientific reports2025
Identification and validation of glucocorticoid receptor and programmed cell death-related genes in spinal cord injury using machine learning.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Deferoxamine mitigates neuronal loss following spinal cord injury via ferroptosis inhibition and Nrf2/HO‑1 pathway activation.International journal of molecular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Spinal cord injury (SCI) is a severe neurological disorder, with glucocorticoids like methylprednisolone commonly used for treatment. However, their efficacy and risks remain controversial. Programmed cell death (PCD) mechanisms have been increasingly implicated in SCI pathology. This study aimed to identify differentially expressed genes (DEGs) related to glucocorticoid receptors and PCD and to construct a diagnostic model to guide glucocorticoid use in SCI treatment. SCI datasets (GSE5296, GSE47681, GSE151371, and GSE45550) were analyzed using protein-protein interaction networks, consensus clustering, GSVA for PCD pathway enrichment, and WGCNA. A total of 113 diagnostic models were developed through 12 machine learning algorithms, with the optimal model, "Lasso + Stepglm[both]," featuring six genes: Abca1, Cdh1, Glipr1, Glt8d2, Il10ra, and Pde5a. Validation through qRT-PCR confirmed the differential expression of four genes (Abca1, Glipr1, Il10ra, and Cdh1), which demonstrated strong predictive performance. Pathway enrichment of GRRDEGs was analyzed using GO, KEGG, and Bayesian network methods, and immune cell infiltration was assessed via CIBERSORT. In this study, we identified GR- and PCD-related DEGs in SCI and constructed a diagnostic model that may improve understanding of SCI molecular mechanisms and inform future investigations of glucocorticoid use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.